7th Mar 2016 09:25
LONDON (Alliance News) - Oxford BioMedica PLC said Monday it has expanded its collaboration with Seattle-based immunotherapy company Immune Design Corp, as well as securing a non-exclusive intellectual property licence deal with the company.
The licence involves the use of lentiviral vector-based products for the treatment of cancer, the company said. Financial and other terms of the deal were not disclosed.
"We are delighted to sign an IP licence and an expanded collaboration agreement with Immune Design. Oxford BioMedica has world-leading capabilities in lentiviral vector process development and manufacture and these agreements with Immune Design are further evidence of our attractiveness as a partner to other companies and academic institutions working with lentiviral vector based products. I expect that during 2016 we will be able to make further announcements of similar agreements with other parties," said Chief Executive Officer John Dawson in a statement.
Shares in Oxford BioMedica were up 3.9% at 6.81 pence Monday morning.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
Oxford Biomedica